Side-by-Side Comparison
Tesamorelin vs Semaglutide: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how Tesamorelin and Semaglutide differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Also: Egrifta, TH9507
An FDA-approved GHRH analog used for HIV-associated lipodystrophy, with research into broader metabolic and cognitive applications.
Also: Ozempic, Wegovy, Rybelsus
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.
Side-by-side comparison
| Attribute | Tesamorelin | Semaglutide |
|---|---|---|
| Primary mechanism | GHRH Receptor Agonism | GLP-1 Receptor Agonism |
| FDA status | FDA Approved | FDA Approved |
| Evidence level | FDA Approved | FDA Approved |
| Human trials | Yes (12+ indexed) | Yes (100+ indexed) |
| Studies indexed | 36 total (18 human, 8 animal) | 630 total (380 human, 120 animal) |
| Primary uses researched | Visceral fat reduction, HIV lipodystrophy, Cognitive function (research) | Weight management, Type 2 diabetes, Cardiovascular risk reduction |
| Administration routes | subcutaneous | oral, subcutaneous |
| Molecular weight | 5135.93 Da | 4113.58 Da |
| Amino acids | 44 | 31 |
| Category | growth hormone | weight loss |
| WADA status | Prohibited | Permitted |
Key differences
Mechanism. Tesamorelin acts primarily through ghrh receptor agonism, while Semaglutide acts primarily through glp-1 receptor agonism. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. Both compounds share the same FDA status (FDA Approved), which means the practical pathway to access is similar for each.
Evidence base. Both compounds currently sit at L5 (FDA Approved) on PeptideMark's methodology.
Research focus. Published research on Tesamorelin has concentrated on visceral fat reduction, hiv lipodystrophy, cognitive function (research). Research on Semaglutide has concentrated on weight management, type 2 diabetes, cardiovascular risk reduction. These research programs have limited overlap, and comparisons are most useful when readers are evaluating adjacent therapeutic goals.
Safety snapshot
| Attribute | Tesamorelin | Semaglutide |
|---|---|---|
| Documented effects | 9 total | 14 total |
| Serious events | 0 | 1 |
| Common events | 5 | 5 |
| Black box warning | No | Yes |
| Contraindications | 4 listed | 3 listed |
| Drug interactions | 2 flagged | 3 flagged |
| Most common event | Injection site reactions | Nausea |
Strengths & limitations
Tesamorelin
Strengths
- FDA-approved with established regulatory record
- Strong evidence base (L5)
- Multiple human clinical trials (12+ indexed)
Limitations
- Prohibited in competitive sport under WADA
Semaglutide
Strengths
- FDA-approved with established regulatory record
- Strong evidence base (L5)
- Multiple human clinical trials (100+ indexed)
- Large indexed research base (630 studies)
Limitations
- Carries an FDA black box warning
Representative studies
Tesamorelin
Tesamorelin, a Growth Hormone–Releasing Factor Analogue, Reduces Visceral Fat in HIV-Infected Patients
Falutz J, et al. · Annals of Internal Medicine (2007)
Tesamorelin reduced visceral adipose tissue by 15.4% compared to placebo, without worsening glucose tolerance.
PubMed 17909207REDUCE-1: Tesamorelin in HIV-Associated Lipodystrophy — A Randomized Controlled Trial
Grunfeld C, Thompson M, Brown SJ, et al. · AIDS (2006)
Tesamorelin reduced visceral AT by 18.3% versus 8.3% placebo (p<0.001); improvement sustained at 26 weeks post-treatment.
PubMed 16816556Semaglutide
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding JPH, Batterham RL, Calanna S, et al. · New England Journal of Medicine (2021)
Semaglutide 2.4mg weekly resulted in 14.9% mean body weight reduction, with 86.4% achieving ≥5% and 50.5% achieving ≥15% weight loss.
PubMed 33567185Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)
Garvey WT, Batterham RL, Bhatt DL, et al. · Nature Medicine (2022)
Semaglutide 2.4mg maintained 15.2% weight loss at 2 years, demonstrating durable efficacy with continued treatment.
PubMed 36356234Frequently asked
What is the main difference between Tesamorelin and Semaglutide?
Tesamorelin is an fda-approved ghrh analog used for hiv-associated lipodystrophy, with research into broader metabolic and cognitive applications. Its primary mechanism is ghrh receptor agonism. Semaglutide is an fda-approved glp-1 receptor agonist used for type 2 diabetes and chronic weight management. Its primary mechanism is glp-1 receptor agonism. The two differ in regulatory status (FDA Approved vs FDA Approved), strength of evidence (L5 vs L5), and the primary conditions for which each is researched.
Is Tesamorelin or Semaglutide FDA approved?
Tesamorelin: FDA-approved in 2010 as Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Semaglutide: FDA-approved GLP-1 receptor agonist. Ozempic approved for type 2 diabetes (2017). Wegovy approved for chronic weight management (2021) and cardiovascular risk reduction (2024).
How does the evidence base compare?
Tesamorelin has 36 indexed studies (18 human, 8 animal) and is rated FDA Approved. Semaglutide has 630 indexed studies (380 human, 120 animal) and is rated FDA Approved. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can Tesamorelin and Semaglutide be compared directly?
Tesamorelin and Semaglutide come from different therapeutic categories (growth hormone vs weight loss), so direct clinical comparison is limited. Readers often compare them because of overlapping research interest, shared patient populations, or adjacent mechanisms — not because head-to-head trial data exists.
Are Tesamorelin and Semaglutide commonly stacked together?
There is no widely documented stacking protocol combining Tesamorelin and Semaglutide in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, Tesamorelin or Semaglutide?
Tesamorelin has 9 documented side effects (0 serious). Semaglutide has 14 documented side effects (1 serious, including a black box warning). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are Tesamorelin and Semaglutide administered?
Tesamorelin is typically administered via subcutaneous. Semaglutide is typically administered via oral or subcutaneous. Route differences affect onset, peak levels, and patient convenience.
Which is better, Tesamorelin or Semaglutide?
"Better" depends on the therapeutic goal, regulatory context, and individual response. Tesamorelin is most researched for visceral fat reduction and hiv lipodystrophy; Semaglutide is most researched for weight management and type 2 diabetes. FDA status also matters: FDA Approved for Tesamorelin vs FDA Approved for Semaglutide. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
Tesamorelin →
Full profile
Semaglutide →